Showing 3081-3090 of 4649 results for "".
- Sensus Healthcare Appoints Dr. Mark Nestor as Clinical Directorhttps://practicaldermatology.com/news/20130830-sensus_healthcare_appoints_dr_mark_nestor_as_clinical_director/2459470/Mark Nestor, MD, PhD has been appointed as Clinical Director of Sensus Healthcare. Dr. Nestor will lead the company's efforts in the areas of training, education, and clinical research as Se
- National Psoriasis Foundation Awards Research Grantshttps://practicaldermatology.com/news/20130610-national_psoriasis_foundation_awards_research_grants/2459519/Six scientists received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for psoriasis and psoriatic arthritis. Theoharis Theoharides, MD, PhD received a
- Houston Surgeon Performs Breakthrough Robotic Hair Restorationhttps://practicaldermatology.com/news/20130402-houston_surgeon_performs_breakthrough_robotic_hair_restoration/2459574/Restoration Robotics, Inc. installed its revolutionary ARTAS System at the Mosaic Clinic in Houston, TX. Dr. Rashid Rashid is one of the few hair physicians in the country to hold both MD and PhD degrees and an enhanced background in r
- Lumiere Medical Announces Dinner Serieshttps://practicaldermatology.com/news/20121003-lumiere_medical_announces_dinner_series/2459715/Lumiere Medical's Innovative MD Academy Regional Dinner Series will be held through the month of October. The company invites physician and medical spa owners to learn about the future of anti-aging and body contouring, w
- App Launched for Medical Entrepreneurshttps://practicaldermatology.com/news/20120824-app_launched_for_medical_entrepreneurs/2459746/The free Medical Entrepreneur App went live on the Apple Store this month. The app, developed by Steven M. Hacker, MD, provides healthcare providers and medical students with business intelligence and decision making tools before, duri
- Nickel Reactions on the Rise. Diet to Blame?https://practicaldermatology.com/news/20120302-nickel_reactions_on_the_rise_diet_to_blame/2459857/Certain patients consuming healthy diets consisting of whole grains, legumes, nuts, and soy may be at increased risk of developing allergic reactions to nickel, according to dermatologist Matthew Zirwas, MD, an associate professor at
- New IL-13/IL-31R Bispecific Antibody Data Presented at EAACIhttps://practicaldermatology.com/news/New-IL-13-IL-31R-Bispecific-Antibody-Data-Presented-EAACI/2475170/A new IL-13/IL-31R bispecific antibody demonstrated ability to simultaneously suppress the inflammatory and pruritogenic pathways in atopic dermatitis (AD), according to preclinical study data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, S
- Skin Cancer Champions Hosts Event to Brainstorm for Growth, Sustainabilityhttps://practicaldermatology.com/news/Skin-Cancer-Champions-Hosts-Event-Brainstorm-Growth-Sustainability/2471116/The Skin Care Champions nonprofit hosted an innovation tournament at Brigham and Women’s Hospital on February 3, bringing together clinicians, patients, caregivers, industry, and more to brainstorm ideas for the organization to achieve growth and sustainability in the future. Emily S. Ruiz
- JAK Inhibitors May Help Eosinophilic Colitis in AD Patientshttps://practicaldermatology.com/news/jak-inhibitors-may-help-eosinophilic-colitis-ad-patients/2468766/Janus kinase (JAK) inhibitors show promise in managing eosinophilic colitis (EoC) in adults with coexisting atopic dermatitis (AD), according to results from a novel case series. Researchers publishing in The Clinical Journal of Gastroenterology presented four cases of adult EoC s
- FDA Approves Up To 3 Tubes of Ameluz Topical Gel, 10% In 1 Treatmenthttps://practicaldermatology.com/news/fda-approves-3-tubes-ameluz-topical-gel-10-1-treatment/2468368/The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to increase the maximally approved dosage from one to three tubes of Biofrontera Inc.’s Ameluz® per treatment, the company announced. Biofrontera Inc. said in a press release that the approval